"10.1371_journal.pmed.0030516","plos medicine","2006-12-12T00:00:00Z","Kay L Pogue-Geile; Ru Chen; Mary P Bronner; Tatjana Crnogorac-Jurcevic; Kara White Moyes; Sally Dowen; Carol A Otey; David A Crispin; Ryan D George; David C Whitcomb; Teresa A Brentnall","Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America; Department of Medicine, University of Washington, Seattle, Washington, United States of America; Department of Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America; Molecular Oncology Unit, Cancer Research United Kingdom, Barts and the London School of Medicine and Dentistry, London, United Kingdom; Department of Cell and Molecular Physiology, University of North Carolina at Chapel Hill, North Carolina, United States of America; Department of Cell Biology and Physiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America; Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America","KLPG, RC, MPB, TCJ, CAO, DAC, DCW, and TAB designed the study. KLPG, RC, MPB, KWM, CAO, DAC, DCW, and TAB analyzed the data. MPB and TAB enrolled patients. KLPG, RC, MPB, KW, CAO, DAC, DCW, and TAB contributed to writing the paper. TAB, KWM, KLPG, RC, MPB, SD, and DAC collected data or did experiments for the study. KWM and RC performed PCR and sequence analysis of candidate genes, plasmid construction and HeLa cell culture and transfections. KLPG and RDG printed the microarray, hybridized RNA from pancreatic tissue samples to the customized microarray, and collected data.","TAB is in the process of filing a patent for the use of palladin as a marker for pancreatic cancer; KLPG, RC, DCW are participants in the same patent application.","2006","12","Kay L Pogue-Geile","KLPG",11,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
